An immediate voluntary recall of 14 lots of Lo/Ovral-28 (norgestrel and ethinyl estradiol) tablets and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets?about 1 million packets?was issued on February 1 by Pfizer after an internal investigation reported that some of the blister packs may contain an inexact count of inert or active ingredient tablets and that the tablets may be out of sequence, increasing the risk of an unintended pregnancy among women using the pills for contraception.
An immediate voluntary recall of 14 lots of Lo/Ovral-28 (norgestrel and ethinyl estradiol) tablets and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets-about 1 million packets-was issued on February 1 by Pfizer after an internal investigation reported that some of the blister packs may contain an inexact count of inert or active ingredient tablets and that the tablets may be out of sequence, increasing the risk of an unintended pregnancy among women using the pills for contraception.
Pfizer notified the US Food and Drug Administration, healthcare providers, and consumers of the recall on February 1.
Akrimax Pharmaceuticals distributed the product to warehouses, clinics, and retail pharmacies throughout the United States. The pills are sold in packs containing 21 tablets of active ingredients and 7 tablets with inactive ingredients. Expiration dates printed on the affected lots are from July 31, 2013 through March 31, 2014.
A complete list of lot numbers for the branded and generic formulations is posted at http://www.fda.gov/Safety/Recalls/ucm289770.htm. FDA and Pfizer advise women who have packets of pills in the affected lots to notify their physicians, return the product to the pharmacy, and begin using a second form of birth control immediately.
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Study finds pregnancy risks higher with ART in kidney transplant recipients
July 11th 2025Women with kidney transplants who conceive through assisted reproductive technology face increased risks of complications such as hypertension, preterm birth, and cesarean delivery, according to new research.
Read More